Mon 17th Jul 2017
UK bio industry receives support for post-Brexit coordination of medicines regulation
The UK BioIndustry Association is celebrating getting a public commitment from government ministers via a letter to the Financial Times calling for post Brexit co-operation with the EU on medicines regulation.
The Association’s CEO, Steve Bates, described this as the 'first step to a sensible approach to Brexit for our sector', which 'recognises the negative impact in areas like falsified medicine, pharmacovigilance and infectious disease control that a cliff edge Brexit would cause on both sides of the channel.'
Page White and Farrer is a member of the UK BioIndustry Association.
This briefing is for general information purposes only and should not be used as a substitute for legal advice relating to your particular circumstances. We can discuss specific issues and facts on an individual basis and answer any questions you may have. Please note that the law may have changed since the day this was first published in July 2017.